Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer.
Clinical Chemistry , Volume 50 - Issue 8 p. 1445- 1447
|Adult, Aged, Aged, 80 and over, Breast Neoplasms/*diagnosis/*drug therapy/pathology, Crk-Associated Substrate Protein, Enzyme-Linked Immunosorbent Assay, Estrogen Antagonists/*therapeutic use, Female, Humans, Middle Aged, Predictive Value of Tests, Proteins/*analysis, Research Support, Non-U.S. Gov't, Retinoblastoma-Like Protein p130, Tamoxifen/*therapeutic use, Tumor Markers, Biological/*analysis|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Dorssers, L.C.J, Grebenchtchikov, N, Brinkman, A, Look, M.P, Klijn, J.G.M, Geurts-Moespot, A, … Sweep, C.G. (2004). Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer. Clinical Chemistry, 50(8), 1445–1447. doi:10.1373/clinchem.2004.035493